NASDAQ:ETON

Eton Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ETON

*Your capital is at risk

$46.42

-2.61 (-5.32%)

At Close: Jul 31, 2026

Eton Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -81.84. In total, the insiders bought 1.76M and sold 1.05M ETON shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-81.84
● Buy	1.76M shares
● Sell	1.05M shares
57% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jun 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -81.84. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 26, 2026 Buy	Employee Stock Option M-Exempt	Krempa David Chief Business Officer	Officer	12 524 Value: $17.2K
May 26, 2026 Buy	Common Stock M-Exempt	Krempa David Chief Business Officer	Officer	25 000 Value: $34.5K
May 26, 2026 Buy	Common Stock M-Exempt	Krempa David Chief Business Officer	Officer	12 524 Value: $17.2K
May 26, 2026 Sell	Common Stock S-Sale	Krempa David Chief Business Officer	Officer	37 524 Value: $1.18M
May 26, 2026 Buy	Employee Stock Option M-Exempt	Krempa David Chief Business Officer	Officer	25 000 Value: $34.5K
May 22, 2026 Sell	Common Stock S-Sale	Krempa David Chief Business Officer	Officer	519 Value: $18.2K
May 22, 2026 Buy	Common Stock M-Exempt	Krempa David Chief Business Officer	Officer	30 591 Value: $109.5K
May 22, 2026 Buy	Employee Stock Option M-Exempt	Krempa David Chief Business Officer	Officer	30 591 Value: $109.5K
May 22, 2026 Sell	Common Stock S-Sale	Krempa David Chief Business Officer	Officer	32 963 Value: $1.10M
May 22, 2026 Sell	Common Stock S-Sale	Krempa David Chief Business Officer	Officer	9 315 Value: $315.6K
Apr 21, 2026 Buy	Common Stock M-Exempt	Riedel Norbert G Director	Director	19 655 Value: $169.2K
Apr 21, 2026 Buy	Common Stock M-Exempt	Riedel Norbert G Director	Director	12 500 Value: $91.4K
Apr 21, 2026 Buy	Employee Stock Option (Right to Buy) M-Exempt	Riedel Norbert G Director	Director	12 500 Value: $91.4K
Apr 21, 2026 Buy	Employee Stock Option (Right to Buy) M-Exempt	Riedel Norbert G Director	Director	19 655 Value: $169.2K
Feb 03, 2026 Buy	Common Stock X-InTheMoney	Riedel Norbert G Director	Director	30 000 Value: $132.6K
Feb 03, 2026 Sell	Employee Stock Option (Right to Buy) X-InTheMoney	Riedel Norbert G Director	Director	30 000 Value: $132.6K
Jan 14, 2026 Sell	Common Stock F-InKind	Krempa David Chief Business Officer	Officer	1 942 Value: $30.3K
Jan 14, 2026 Sell	Common Stock F-InKind	Gruber James R. Chief Financial Officer	C-Suite Officer	2 293 Value: $35.5K
Jan 12, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Brynjelsen Sean President & CEO	CEO / President	158 046 Value: $2.44M
Jan 12, 2026 Buy	Restricted Stock Units A-Award	Brynjelsen Sean President & CEO	CEO / President	100 517 Value: $1.55M
Jan 12, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Erdogan-trinkaus Ipek Chief Commercial Officer	Officer	40 655 Value: $628.9K
Jan 12, 2026 Buy	Restricted Stock Units A-Award	Erdogan-trinkaus Ipek Chief Commercial Officer	Officer	25 856 Value: $400.0K
Jan 12, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Maier Paul V Director	Director	12 196 Value: $188.7K
Jan 12, 2026 Buy	Restricted Stock Units A-Award	Riedel Norbert G Director	Director	7 757 Value: $120.0K
Jan 12, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Riedel Norbert G Director	Director	12 196 Value: $188.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ETON PHARMACEUTICALS INC.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezip...

Read Full Profile Here